Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma

Simple Summary During the last decades, the CA 19-9 blood test has been the only widely used biomarker in patients with pancreatic ductal adenocarcinoma (PDAC). Given the poor prognosis and staggering mortality rates of this type of cancer, partly due to late diagnosis, new and easily available biomarkers are in high demand. Using a large cohort of patients with PDAC, we found that a combination of CA 19-9 and sCD163 blood tests was a superior diagnostic marker compared to the recommended CA 19-9 test alone. Our findings suggest that sCD163 could have clinical value as a novel, minimally invasive, and cost-effective diagnostic marker. However, because this is the first study examining sCD163 in patients with PDAC, further studies are needed to validate our findings. Abstract The objective of this study was to evaluate the diagnostic and prognostic potential of soluble CD163 (sCD163) in patients with pancreatic ductal adenocarcinoma (PDAC). Preoperative serum samples from 255 patients with PDAC were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay. The diagnostic value of sCD163 was evaluated using receiver operating characteristic (ROC) curves. The prognostic significance of sCD163 was evaluated by Cox regression analysis and Kaplan–Meier survival curves. sCD163 was significantly increased in patients with PDAC, across all stages, compared to healthy subjects (stage 1: p value = 0.033; stage 2–4: p value ≤ 0.0001). ROC curves showed that sCD163 combined with CA 19-9 had the highest diagnostic potential compared to sCD163 and CA 19-9 alone both in patients with local PDAC and patients with advanced PDAC. Univariate and multivariate analysis showed no association between sCD163 and overall survival. This study found elevated levels of circulating sCD163 in patients with PDAC, regardless of stage, compared to healthy subjects. This suggests that sCD163 may have a clinical value as a novel diagnostic biomarker in PDAC.

[1]  Z. Szallasi,et al.  Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy , 2022, Cancers.

[2]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[3]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[4]  Tao Huang,et al.  The Scavenger Receptor MARCO Expressed by Tumor-Associated Macrophages Are Highly Associated With Poor Pancreatic Cancer Prognosis , 2021, Frontiers in Oncology.

[5]  L. Matrisian,et al.  Estimated Projection of US Cancer Incidence and Death to 2040 , 2021, JAMA network open.

[6]  H. Holte,et al.  Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma , 2021, Haematologica.

[7]  Hongwei Wang,et al.  Serum insulin‐like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma‐associated malnutrition and muscle wasting , 2021, Journal of cachexia, sarcopenia and muscle.

[8]  Z. Szallasi,et al.  Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification , 2021, Clinical Cancer Research.

[9]  Yihai Cao,et al.  Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism , 2021, Gut.

[10]  R. Turkington,et al.  Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta‐analysis , 2021, The journal of pathology. Clinical research.

[11]  N. Malats,et al.  Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma , 2021, International journal of cancer.

[12]  D. Hayes.  Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Hong Zhang,et al.  Is sCD163 a Clinical Significant Prognostic Value in Cancers? A Systematic Review and Meta-Analysis , 2020, Frontiers in Oncology.

[14]  R. Tollenaar,et al.  CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood , 2020, International journal of molecular sciences.

[15]  A. Abe,et al.  CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast , 2020, Virchows Archiv.

[16]  S. Bojesen,et al.  Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[17]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[18]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[19]  P. Radhakrishnan,et al.  Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis , 2019, Molecular Cancer.

[20]  W. Sauerbrei,et al.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration , 2018, Journal of the National Cancer Institute.

[21]  S. Natsugoe,et al.  Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. , 2018, Experimental and therapeutic medicine.

[22]  Dongbing Ding,et al.  Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer , 2017, Oncology letters.

[23]  S. Leach,et al.  Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers , 2017, Clinical Cancer Research.

[24]  R. Advani,et al.  Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial , 2016 .

[25]  J. Hutcheson,et al.  Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease , 2016, Clinical Cancer Research.

[26]  H. Møller,et al.  Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma , 2016, Scandinavian journal of clinical and laboratory investigation.

[27]  R. Gascoyne,et al.  The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association , 2015, Clinical Cancer Research.

[28]  H. Møller,et al.  Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia , 2015, Leukemia & lymphoma.

[29]  K. H. Huang,et al.  Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China. , 2014, Current oncology.

[30]  H. Møller,et al.  Monocyte/macrophage‐derived soluble CD163: a novel biomarker in multiple myeloma , 2014, European journal of haematology.

[31]  J. Trojan,et al.  Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. , 2013, Journal of hepatology.

[32]  Kidong Kim,et al.  Prognostic Significance of Serum Soluble CD163 Level in Patients with Epithelial Ovarian Cancer , 2013, Gynecologic and Obstetric Investigation.

[33]  S. Natsugoe,et al.  Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. , 2011, The Journal of surgical research.

[34]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[35]  H. Møller,et al.  Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Vogel,et al.  Up‐regulation of human monocyte CD163 upon activation of cell‐surface Toll‐like receptors , 2007, Journal of leukocyte biology.

[37]  S. Moestrup,et al.  CD163: a regulated hemoglobin scavenger receptor with a role in the anti‐inflammatory response , 2004, Annals of medicine.

[38]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[39]  S. Moestrup,et al.  Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. , 2002, Blood.

[40]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[41]  H. Hansen,et al.  Performance status assessment in cancer patients. An inter-observer variability study. , 1993, British Journal of Cancer.

[42]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.